$1.34
-0.04-2.9%
Last update: Nov 12, 1:28 PM
Cellectis SA
CLLSNASDAQ
Cellectis fell 62.2% from $3.65 to $1.38, behind the S&P 500's +11.2%. Its worst day was Sep 14 (−41.0%), and its low came Oct 19 at $0.93.
Nov 12, 2025 – Nov 11, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Cellectis closed at its highest level of the year, 46.6% above where the year started.
+14.1% · S&P 500 +1.5%
Cellectis shares fell 15.2%, while the S&P 500 fell 0.3%.
Story events cover the past 12 months · Times ET
−15.2% · S&P 500 −0.3%
EPS of $-0.24 missed the $-0.10 estimate on $12.2M revenue (est. $10.7M).
−4.0% · S&P 500 −1.4%
Cellectis shares rose 19.2%, while the S&P 500 rose 1.0%.
+19.2% · S&P 500 +1.0%
EPS of $-0.16 beat the $-0.26 estimate on $7.5M revenue (est. $9.4M).
−0.5% · S&P 500 −0.2%
EPS of $-0.19 beat the $-0.26 estimate on $6.9M revenue (est. $9.4M).
+5.2% · S&P 500 +0.6%
Cellectis to advance two lead in vivo programs .HEAL-101 and .HEAL-201 in severe dyslipidemias with preliminary Phase 1 data planned in H2 2027 and H1 2028, respectivelyTransformation supported by continuing existing
−41.0%, the year's worst day, on 1M shares, the year's heaviest volume · S&P 500 −0.4%
Cellectis closed at its lowest level of the year, 74.6% below where the year started.
−11.0% · S&P 500 +0.4%
Cellectis shares rose 20.0%, while the S&P 500 rose 0.3%.
+20.0% · S&P 500 +0.3%
Where it ended: a close of $1.38 on Nov 11, 2026. Up next: Q3 2026 earnings on Nov 12, 2026 (EPS est. $-0.18, revenue est. $13.5M).
Nothing in the past 12 months.
All CLLS dividend historyReplay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for CLLS and SPY from Benzinga historical bars. Not investment advice.
